CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞的早期和晚期毒性
英文原题：Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
查看英文原题
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
随着嵌合抗原受体（CAR）T细胞疗法在多种恶性肿瘤的临床实践中日益普及，识别和治疗炎症性毒性对于治疗成功至关重要。CD19靶向CAR-T 细胞疗法的早期经验将细胞因子释放综合征和神经毒性确定为关键的急性毒性，并促成了统一的倡议以减轻这些并发症的影响。在本节中，我们提供CAR-T 细胞相关毒性当前状态的更新，重点关注影响其他器官系统的新兴急性毒性，以及对延迟毒性和晚期效应的考虑。
展开英文摘要原文
As chimeric antigen receptor (CAR) T-cell therapy is increasingly integrated into clinical practice across a range of malignancies, identifying and treating inflammatory toxicities will be vital to success. Early experiences with CD19-targeted CAR T-cell therapy identified cytokine release syndrome and neurotoxicity as key acute toxicities and led to unified initiatives to mitigate the influence of these complications.
In this section, we provide an update on the current state of CAR T-cell-related toxicities, with an emphasis on emerging acute toxicities affecting additional organ systems and considerations for delayed toxicities and late effects.
论文信息
- 作者
- Epperly R、Giordani VM、Mikkilineni L、Shah NN
- 第一作者单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 1130, Memphis, TN 38105, USA.United States
- 通讯作者单位
- Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Building 10, Room 1W-3750, 9000 Rockville Pike MSC 1104, Bethesda, MD 20892, USA. Electronic address: nirali.shah@nih.gov.United States
- 文献类型
- 综述 · 美国 NIH 院内研究
- 期刊
- Hematology/oncology clinics of North America2023 Dec
- 原文标识
- PubMed 37349152 · DOI 10.1016/j.hoc.2023.05.010
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →